Quantification and characterization of granulocyte macrophage colony-stimulating factor activated human peripheral blood mononuclear cells by fluorine-19 cellular MRI in an immunocompromised mouse model

Authors

C Fink
M Smith
O C SehlFollow
J M Gaudet
T C Meagher
N A Sheikh
Jimmy DikeakosFollow
Michael Rieder, University of Western OntarioFollow
P J Foster
G A DekabanFollow

Document Type

Article

Publication Date

9-1-2020

Journal

Diagnostic and Interventional Imaging

Volume

101

Issue

9

First Page

577

Last Page

588

URL with Digital Object Identifier

https://doi.org/10.1016/j.diii.2020.02.004

Abstract

PURPOSE: The purpose of this study was to test fluorine-19 (19F) cellular magnetic resonance (MRI) as a non-invasive imaging modality to track therapeutic cell migration as a surrogate marker of immunotherapeutic effectiveness.

MATERIALS AND METHODS: Human peripheral blood mononuclear cell- (PBMC)-derived antigen presenting cell (APC) were labeled with a 19F-perfluorocarbon (PFC) and/or activated with granulocyte macrophage colony-stimulating factor (GM-CSF). Viability, phenotype and cell lineage characterization preceded 19F cellular MRI of PFC

RESULTS: A high proportion of PBMC incorporated PFC without affecting viability, phenotype or cell lineage composition. PFC

CONCLUSION: 19F cellular MRI is a non-invasive imaging technique capable of detecting and quantifying in vivo cell migration in conjunction with an established APC-based immunotherapy model. 19F cellular MRI can function as a surrogate marker for assessing and improving upon the therapeutic benefit that this immunotherapy provides.

Notes

This article was first published in Diagnostic and Interventional Imaging at https://doi.org/10.1016/j.diii.2020.02.004.

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.